Houdini Bio has raised approximately £1.5 million in grants and pre-seed funding led by SCVC, the venture arm of Science Creates. Cambridge Enterprise VC and Deep Science Ventures also participated in the oversubscribed round. Founded in 2025, the Cambridge spinout has developed software that redesigns therapeutic DNA to prevent the body's HUSH protein complex from silencing it. The company claims its approach can increase gene expression more than tenfold compared to current methods, addressing a critical durability problem in gene and cell therapies. Chief executive Jonathan Cohen-Gold discovered the molecular workaround during his PhD at Cambridge. The startup will use the funding to expand its team and establish co-development partnerships with pharmaceutical companies. The global gene therapy market is projected to grow from $10.04 billion in 2026 to $25.89 billion by 2031.

Ramaiah Academy Foundation collaborates with Dassault Systemes to accelerate Deep Science translation in India. Desk News Super Admin Jun 8, 2026 - 7:00 PM 0 0 "Ramaiah Academy Foundation collaborates with Dassault Systemes to accelerate Deep Science translation in India" Read more on attentionworlds.com 8 Jun 2026 The Ramaiah Academy Foundation (RAF) and Dassault Systemes today announced their collaboration aimed at bridging the critical gap between academic research and commercial-scale manufacturing. Central to this collaboration is the establishment of a Deep Science Translational Innovation Complex in Bengaluru, designed to accelerate productization in high-impact sectors including Aerospace & Defense, Healthcare & MedTech, Automotive, and Semiconductors. MoU exchange between Venkatesh Valluri, Vice Chairman, Ramaiah Academy Foundation, and Deepak N.G., Managing Director-India, Dassault Systemes This collaboration represents a first-of-its-kind model in the region, transitioning beyond a traditional academic arrangement into a fully integrated, go-to-market commercial partnership. It seamlessly leverages Dassault Systemes' globally recognized 3DEXPERIENCE platform alongside Ramaiah's deep science expertise and advanced prototyping infrastructure. This synergistic relation between RAF and Dassault Systemes aims to enhance the value for companies focused on enhancing their conceptual research & innovation; skill development of their engineers for newer projects; and acquiring newer talent. "This collaboration represents a paradigm shift in how academia and industry collaborate in India. We are moving beyond transactional skill development into a technology l translation engine," said Venkatesh Valluri, Vice Chairman, Ramaiah Academy Foundation. "Through the Deep Science translation complex, we are providing an end-to-end value chain, from problem definition and virtual twin simulation to physical lab-scale manufacturing," Valluri continued. "Our joint vision is to foster national-level 'projects' that embody the true spirit of Make-in-India, equipping both our industrial partners and our engineering talent with the world's most advanced technological tools." "At Dassault Systemes, we believe that shaping the future of industrial innovation starts with empowering the next generation of engineers and thinkers in the virtual world," said Deepak NG, Managing Director, India, Dassault Systemes. Our collaboration with the Ramaiah Academy Foundation reflects a shared commitment to bridging the gap between academia and industry through platform-driven learning. We aim to foster a culture of sustainable innovation and advanced engineering excellence that will drive India's high-tech and manufacturing ecosystems forward," he stated further. The Deep Science translational facility, currently undergoing advanced modifications on the Ramaiah campus in Bengaluru, will house state-of-the-art technical teaching centers, collaborative design spaces, and lab-scale manufacturing zones. About Ramaiah Academy Foundation The Ramaiah Academy Foundation (RAF), a Section 8 not-for-profit company, is a distinguished institution within the Gokula Education Foundation (Medical) ecosystem, carrying forward the legacy of excellence established by the renowned Ramaiah Group. Committed to fostering innovation, advancing applied sciences, and nurturing future-ready talent, the Foundation serves as a catalyst for transformative education, translational research, and industry collaboration. Founded with a vision to bridge the gap between academic discovery and real-world application, Ramaiah Academy Foundation focuses on creating impactful pathways that connect research, technology, entrepreneurship, and industrial growth. The Foundation actively promotes interdisciplinary learning, deep technology development, and innovation-led ecosystems that address emerging global challenges while contributing to India's scientific and economic progress. At the heart of its vision is the development of a world-class Translational Innovation Complex, a pioneering initiative designed to accelerate the journey of scientific discoveries from laboratories to large-scale commercial applications. The Complex will function as a robust commercial and innovation engine, addressing one of the most critical challenges in the research ecosystem - the Technology Readiness Level (TRL) gap. By enabling the seamless transition of technologies from proof-of-concept and prototype stages to scalable industrial manufacturing, the Foundation aims to create a sustainable bridge between academia, research institutions, startups, industry partners, and investors. The Translational Innovation Complex will provide an integrated platform for advanced research, product development, prototyping, testing, validation, and commercialization. It will foster collaboration among scientists, engineers, entrepreneurs, and industry leaders, creating an environment where breakthrough ideas can be transformed into market-ready solutions. Through this ecosystem, the Foundation seeks to accelerate innovation across strategic sectors including advanced materials, life sciences, healthcare technologies, artificial intelligence, robotics, semiconductor technologies, sustainable energy, and other deep-tech domains. Ramaiah Academy Foundation is also committed to developing industry-ready talent through specialized education, skill development, and experiential learning initiatives. By combining academic rigor with practical application, the Foundation equips learners with the knowledge, skills, and mindset required to thrive in an increasingly technology-driven world. Its programs are designed in close collaboration with industry stakeholders, ensuring alignment with evolving workforce requirements and global best practices. Guided by the values of excellence, integrity, innovation, and societal impact, the Foundation strives to create meaningful opportunities for researchers, students, entrepreneurs, and industry partners. Through strategic collaborations with leading academic institutions, research organizations, government agencies, and global industry leaders, it aims to establish a vibrant innovation ecosystem that drives technological advancement and economic development. As India continues its journey toward becoming a global innovation powerhouse, Ramaiah Academy Foundation stands poised to play a pivotal role in shaping the future of research, technology commercialization, and talent development. By transforming ideas into impact and research into real-world solutions, the Foundation is creating a platform where innovation meets industry, knowledge meets opportunity, and vision translates into lasting societal progress. rss_feed Disclaimer Story published through syndicated feed. Publisher:: News Voir admin_panel_settings Disclaimer: This post is officially published by the Administrator. favorite Follow us for the latest updates:

Deep Science Ventures and Medicines Discovery Catapult partner to accelerate next-generation brain treatments. New strategic collaboration aims to overcome long-standing barriers in brain-targeted drug discovery. 2 June 2026 Deep Science Ventures (DSV), a UK-based deeptech venture creator, and Medicines Discovery Catapult (MDC), a life sciences service dedicated to turning drug discovery into commercial breakthroughs, today announced a strategic collaboration to address challenges in delivering medicines into the brain. One of medicine's greatest challenges is ensuring that treatments reach the precise area of the body where they are needed. While recent scientific breakthroughs have identified numerous targets for neurological conditions, the difficulty of effectively transporting these treatments across the blood-brain barrier and into the central nervous system (CNS) remains a primary challenge for global health. According to the World Health Organization's Global Status Report on Neurology, over 40% of the global population is living with CNS diseases, making them a leading global cause of ill health and disability. Developing new solutions could unlock access for rare neurological disorders and expand treatment to large or underserved patient populations, including those with diseases like Alzheimer's and Parkinson's and various brain cancers. Directly addressing critical gaps in healthcare means these innovations have the potential to improve patient outcomes while creating clinical and commercial opportunities for biotech and pharma companies. The first phase of the partnership will see an in-depth review of the current medicines landscape conducted to identify opportunities for innovation. This information will then be used to identify systemic gaps in brain-entry technologies. The long-term ambition is for novel approaches that meet the investment criteria of the partners to be spun out into new ventures focused on high-impact solutions and to provide them with pre-seed funding. A core part of DSV's approach involves building future founding teams to form new companies that will address challenges across multiple sectors. Future founders will work on opportunities that have been pre-scoped by DSV, de-risking the standard founder proposition. By combining DSV's unique venture-building model with MDC's drug discovery expertise and infrastructure, the partnership will develop new approaches to ensure life-changing medicines reach the brain. "The blood-brain barrier remains one of the most complex issues in modern medicine and with over 40% of the world's population facing neurological conditions, it's imperative that we find an optimal solution to this problem," said Adam Tomassi-Russell, Senior Director, Deep Science Ventures. "By pooling our venture-creation expertise with MDC's discovery capabilities, we can offer the right founders a frictionless environment in which to tackle the CNS delivery gap. If we can solve the 'how' of brain entry more effectively, we can unlock a new frontier of CNS therapeutics and address the huge unmet need in these diseases." Dr Nicola Heron, Chief Strategy Officer at Medicines Discovery Catapult, said: "At MDC, we are committed to transforming bold ideas into better treatments. This collaboration presents an opportunity to discover new technologies that could have a significant impact on patients and society. Through this partnership, we will strengthen the ecosystem for CNS innovation in the UK and beyond, enabling more medicines to reach patients faster." Find out more about how MDC's expertise can accelerate drug discovery and make every move count here.